DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.

CONTEXT Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs). OBJECTIVE The clinical and pathological characteristics of APAs and PCs treated with TMZ in Japan were surveyed and analyzed retrospectively. DESIGN Members of the Japan Society of Hypothalamic and Pituitary Tumors were surveyed regarding the clinical characteristics of APAs and PCs treated with TMZ. Stored tumor samples were gathered from the responders and were assessed by the immunohistochemistry of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, p53, MSH6, and anterior pituitary hormones. Responses to TMZ treatment were defined as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) according to RECIST (Response Evaluation Criteria in Solid Tumors) version 2.0. SUBJECTS Three samples from 3 subjects with APA and 11 samples from 10 subjects with PC were available. RESULTS The 13 subjects had APAs and PCs consisting of 5 prolactin-producing tumors, 5 ACTH-producing tumors, and 3 null cell adenomas. The clinical response to TMZ treatment was as follows: 4 cases of CR and PR (31%), 2 cases of SD (15%), 6 cases of recurrence after CR and PR (46%), and 1 case of PD (8%). However, considerable subjects had recurrent disease after a response to TMZ. The immunohistochemical findings of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, and p53 did not show any significant correlation with the efficacy of TMZ. However, the immunopositivity of MSH6 was positively correlated with TMZ response (P = .015, Fisher's exact test). CONCLUSIONS This study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms. It is necessary to survey more cases and evaluate multifactor analyses.

[1]  F. Ducray,et al.  New targeted therapies in pituitary carcinoma resistant to temozolomide , 2012, Pituitary.

[2]  K. Yamazaki,et al.  A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report , 2011, Neurosurgery.

[3]  B. Scheithauer,et al.  Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy , 2011, Hormones.

[4]  B. Scheithauer,et al.  MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas , 2011, Journal of Neuro-Oncology.

[5]  B. Scheithauer,et al.  Treatment of pituitary neoplasms with temozolomide , 2011, Cancer.

[6]  M. Reni,et al.  Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. , 2010, European journal of endocrinology.

[7]  E. Laws,et al.  Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  A. Ashworth,et al.  Therapeutic Targeting of the DNA Mismatch Repair Pathway , 2010, Clinical Cancer Research.

[9]  H. Hammes,et al.  SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[10]  P. Chanson,et al.  Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. , 2010, The Journal of clinical endocrinology and metabolism.

[11]  H. Ikeda,et al.  Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. , 2010, Journal of neurosurgery.

[12]  C. Harris,et al.  Clinical outcomes and correlates of TP53 mutations and cancer. , 2010, Cold Spring Harbor perspectives in biology.

[13]  J. Bruce,et al.  Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor , 2011, Pituitary.

[14]  Shiladitya Sengupta,et al.  p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. , 2009, Anticancer research.

[15]  S. Clark,et al.  Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours , 2009, Clinical endocrinology.

[16]  Stephen Yip,et al.  MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.

[17]  R. McLendon,et al.  MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy , 2008, Acta Neuropathologica.

[18]  B. Scheithauer,et al.  P53 Gene Mutations in Pituitary Carcinomas , 2007, Endocrine pathology.

[19]  B. Skogseid,et al.  Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors , 2007, Clinical Cancer Research.

[20]  P. A. Futreal,et al.  Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment , 2007, Clinical Cancer Research.

[21]  W. Edelmann,et al.  Mismatch repair proteins as sensors of alkylation DNA damage. , 2006, Cancer cell.

[22]  E. Eisenhauer,et al.  Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.

[24]  M. Weller,et al.  O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells , 2006, Journal of neurochemistry.

[25]  M. Buchfelder,et al.  Diagnosis and Management of Pituitary Carcinomas , 2005 .

[26]  B. Scheithauer,et al.  Pituitary Carcinoma: A Clinicopathological Review , 2005, Neurosurgery.

[27]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[28]  C. Ryan,et al.  A phase II trial of oral temozolomide in patients with metastatic renal cell cancer , 2002, Cancer Chemotherapy and Pharmacology.

[29]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. J. Mukherjee,et al.  The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[31]  B. Scheithauer,et al.  Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. , 1996, Neurosurgery.

[32]  B. Scheithauer,et al.  Pathology of invasive pituitary tumors with special reference to functional classification. , 1986, Journal of neurosurgery.